

Review Article

Decoding Multicellularity in *Streptomyces*: Single-Cell Technologies Reveal the Link between Phenotypic Heterogeneity and Secondary Metabolite Production

Loh Teng-Hern Tan^{1,2*}

Article History

Received: 13 September 2025;

Received in Revised Form: 18 November 2025;

Accepted: 30 November 2025;


Available Online: 01 December 2025

¹Microbiome Research Group, Research Centre for Life Science and Healthcare, Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute (CBI), University of Nottingham Ningbo China, Ningbo, 315000, China

²Novel Bacteria and Drug Discovery Research Group (NBDD), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia

*Corresponding author: Loh Teng-Hern Tan; Microbiome Research Group, Research Centre for Life Science and Healthcare, Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute (CBI), University of Nottingham Ningbo China, Ningbo, 315000, China; loh-teng-hern.tan@nottingham.edu.cn (LT-HT)

Abstract: *Streptomyces* species are among the most prolific natural sources of antibiotics and other bioactive secondary metabolites, supporting major therapeutic advances, including streptomycin and ivermectin. In addition to their ecological role as saprophytic decomposers, they remain central to modern medicine and agriculture, with nearly two-thirds of clinically used antibiotics originating directly or indirectly from this genus. Recent progress in genome sequencing, CRISPR-Cas9 editing, and synthetic biology has expanded our ability to modify *Streptomyces* genomes, activate silent biosynthetic gene clusters, remove competing pathways, and increase metabolite output. Yet, industrial use of these bacteria continues to be difficult due to their complex multicellular life cycle and pronounced phenotypic heterogeneity. Even genetically identical cells display differences in germination, growth, and metabolic activity, leading to inconsistent fermentation performance and variable yields. More recent studies have shown that this heterogeneity is not simply a technical barrier but a beneficial ecological strategy that improves survival in changing environments. These findings underscore the need to understand the spatial and temporal diversity that shapes *Streptomyces* biology. New single-cell technologies, including microfluidics and Raman spectroscopy, now allow direct observation of developmental processes, spatial mapping of metabolite production, and high-resolution screening of superior producer strains. This review summarises current advances in engineering *Streptomyces* and examines how single-cell approaches are transforming our understanding of their variability. By combining genetic tools with precise phenotypic analysis, researchers are moving toward more consistent and scalable production systems for valuable natural products.



Graphical abstract. Advancements in single-cell technologies, such as microfluidics and Raman spectroscopy, in decoding *Streptomyces* heterogeneity.

Keywords: *Streptomyces*; secondary metabolites; heterogeneity; microfluidics; Raman spectroscopy; SDG 3 Good health and well-being

1. Introduction

Streptomyces bacteria are among nature's most prolific producers of clinically important antibiotics and other bioactive secondary metabolites ^[1, 2]. For decades, *Streptomyces* has been central to microbiology and therapeutic discovery, contributing to the Nobel Prize-winning drugs such as streptomycin and ivermectin ^[3, 4]. These microorganisms are critical to ecological processes as saprophytes, mineralising complex polymers in soil and aquatic sediments, which facilitates the recycling of organic matter. *Streptomyces* also serve as the primary source of natural products used in medicine and agriculture ^[5]. It is estimated that approximately two-thirds of antibiotics are derived directly or indirectly from *Streptomyces* species ^[6, 7], along with a diverse range of other bioactive compounds, including anticancer, antifungal, antiparasitic, and immunosuppressant agents ^[8-12].

The urgent global challenge of antimicrobial resistance sharpens the relevance of *Streptomyces* research ^[13, 14]. Multidrug-resistant pathogens threaten public health worldwide ^[15-20], and microbial natural products remain one of the richest sources of new chemical scaffolds for antibiotic discovery ^[21, 22]. Renewed efforts to discover, activate and optimise biosynthetic gene clusters are therefore strategic priorities for replenishing the antibiotic pipeline and countering resistant infections ^[23]. These imperatives motivate both fundamental

studies of *Streptomyces* biology and the development of high-throughput, discovery-oriented platforms that can accelerate lead identification and strain improvement.

Recent decades have seen dramatic advances in the genetic manipulation of *Streptomyces*. With the advent of high-throughput genome sequencing, CRISPR-Cas9 based genome editing, and synthetic biology, it is now possible to make precise modifications to the bacterial genome [24-27]. These technologies allow for the deletion of competing metabolic pathways, the activation of silent biosynthetic gene clusters (BGCs), and the optimisation of BGC expression [28-30]. These innovations have unlocked previously cryptic biosynthetic pathways and led to notable successes in enhancing the production of valuable secondary metabolites, providing new opportunities for drug discovery and industrial biotechnology [31, 32]. However, despite these powerful tools, the industrial-scale exploitation of *Streptomyces* remains challenging due to its inherent biological complexity.

One of the central challenges in using *Streptomyces* for large-scale production is its complex, multicellular life cycle [4]. Spore germination gives rise to a branching substrate mycelium that, under nutrient limitation, differentiates to form aerial hyphae and spores; this developmental program is tightly coupled to secondary metabolism, with antibiotic production frequently coinciding with sporulation [33-35]. However, a key feature of this lifecycle is the profound phenotypic heterogeneity observed even within genetically identical populations. Variations in germination timing, growth rates, and metabolic activity among individual cells result in unpredictable batch-to-batch variations and suboptimal yields in industrial fermentations [36, 37].

Nevertheless, recent studies have shifted this perspective, revealing that such heterogeneity serves as a biologically meaningful, adaptive bet-hedging strategy, enhancing the survival of *Streptomyces* populations in the face of fluctuating environmental conditions [34, 38]. This variability occurs across various spatial scales within the colony, from metabolic differences between individual cells within a hyphal filament to larger-scale variations between distinct regions of the mycelial network [39]. While such variability has posed challenges in achieving consistent secondary metabolite production, it also provides critical insights into the complex regulatory networks governing *Streptomyces* biology.

This review aims to illustrate the significant efforts by researchers to engineer *Streptomyces* for the production of secondary metabolites of interest. In doing so, these efforts have uncovered the remarkable heterogeneity within *Streptomyces* populations, which had remained underexplored due to technological constraints. We will highlight how innovations in genetic engineering, combined with advancements in single-cell technologies such as microfluidics and Raman spectroscopy, are unravelling this complexity. These technologies enable researchers to directly observe the life cycles of *Streptomyces* [40], spatially map metabolite production [41, 42], and identify high-producing strains with unprecedented resolution [43-45].

2. Key Genetic Engineering Strategies to Enhance Secondary Metabolite Production in *Streptomyces*

Genetic engineering strategies in *Streptomyces* have long combined classical regulatory manipulation with advanced synthetic biology approaches [46]. These strategies include targeting regulatory genes, manipulating the genetic makeup of the BGC itself, employing heterologous expression, and leveraging advanced genome-editing technologies such as CRISPR-Cas9. Early landmark studies established that pathway-specific activators such as ActII-ORF4 and RedD function as master regulators for the actinorhodin [47] and undecylprodigiosin [48] gene clusters. Increasing their copy number or driving their overexpression reliably activated transcription of the corresponding biosynthetic genes, demonstrating that targeting native *Streptomyces* antibiotic regulatory protein (SARP)-family regulators is an effective way to boost metabolite production [49, 50].

The rapid advancement of whole-genome sequencing technologies has further strengthened these strategies. With thousands of complete or nearly complete *Streptomyces* genomes now publicly available, researchers can comprehensively map regulatory architectures, identify cryptic or silent BGCs, and compare promoter elements and regulatory motifs across species [51–54]. This genomic richness provides a rational foundation for targeted engineering by revealing conserved regulatory logic and cluster organisation. Building on these foundations, promoter engineering has introduced more predictable and tunable control over BGC expression [55]. Strong constitutive promoters such as *kasOp** variants [56], together with synthetic promoter libraries [57, 58], have enabled rational refactoring of operons and BGCs, leading to substantial and reproducible increases in secondary metabolite yields across multiple pathways [59].

More recent approaches have broadened the engineering toolbox and accelerated the pace of discovery, particularly through the application of clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (Cas) system for genome editing in *Streptomyces* [24, 60]. The development of CRISPR-based systems, especially the pCRISPomyces platforms, enabled rapid and efficient genome editing in a wide range of *Streptomyces* species [61]. These tools support multiplex deletions, promoter insertions, and even modular replacement within large polyketide synthase and nonribosomal peptide synthetase clusters, greatly expanding what can be achieved in BGC refactoring [61]. Alongside these targeted methods, ribosome engineering remains a valuable strategy for activating silent gene clusters and boosting metabolite production by selecting mutants in ribosomal proteins or RNA polymerase subunits [62], without prior knowledge of specific regulators.

Finally, improvements at the host and systems level make pathway engineering more predictable [63, 64]. Engineered chassis strains such as *S. lividans* and *S. albus* provide reduced background metabolism and fewer interfering pathways, facilitating heterologous expression [65, 66]. Genome-scale metabolic models (GEMs) and algorithms now guide rational interventions to boost precursor supply and reroute central carbon flux [67]. GEMs is a metabolic engineering approach which predicts the flow of metabolic intermediates and identifies the key

genetic targets for modification, illustrating how modelling and experimentation are combined to raise yields [68–70]. Together, these advances have made the activation of silent BGCs and the scale-up of valuable secondary metabolites far more reliable and efficient.

While genetic engineering strategies have undeniably transformed the potential of *Streptomyces* for the industrial production of secondary metabolites, several challenges remain. The inherent complexity of the *Streptomyces* genome, with its vast regulatory networks and multi-layered biosynthetic pathways, often leads to unpredictable outcomes when manipulating these systems [71]. Moreover, while CRISPR-Cas9 and other advanced tools offer unprecedented precision, issues like off-target effects, genetic instability, and host toxicity still pose significant hurdles for their widespread application [72–74].

The success of these strategies often depends on the specific context, such as the nature of the BGC, the host strain, and the production scale [74]. Consequently, achieving optimal outcomes requires a deep understanding of both the genetic underpinnings of *Streptomyces* and the metabolic engineering tools available. Further advancements in tools like CRISPR-Cas9, genome-scale metabolic modelling, and combinatorial biosynthesis, combined with increased knowledge of *Streptomyces* biology, will likely continue to enhance the ability to activate silent BGCs and maximise the production of high-value secondary metabolites.

3. Multifaceted Nature of *Streptomyces* Heterogeneity

Heterogeneity in *Streptomyces* is a major factor that complicates efforts to optimise secondary metabolite production. Although genetic engineering has improved yields in many strains, the substantial phenotypic variation that arises within clonal populations remains insufficiently understood. This variation is strongly tied to the multicellular life cycle of *Streptomyces*, which begins with spore germination, followed by vegetative mycelial growth, and leads to the formation of aerial hyphae and chains of unigenomic spores [34, 75, 76]. These developmental transitions create distinct cellular states within a colony and lead to differences in growth, morphology, and metabolite secretion, even among genetically identical cells.

Because *Streptomyces* grows as an interconnected mycelial network, spatial heterogeneity naturally emerges, whereby cells in different regions of a colony may experience different nutrient levels, stresses, and signalling cues, resulting in varied gene expression and metabolic behaviour. These differences reflect coordinated developmental and ecological responses rather than random noise. As noted by Hoskisson et al. [34], such within-colony variation allows the population to respond to multiple, rapidly changing environmental inputs at the same time. In soil environments where resources and competition are patchy, this flexibility increases overall survival and fitness. A well-studied example of this functional differentiation is the division of labour created by genomic rearrangements. In *Streptomyces coelicolor*, a small subpopulation of cells (around 1–10%) undergoes major deletions or amplifications near the end of their linear chromosome, producing variants that grow poorly but overproduce antibiotics [76]. Meanwhile, the rest of the population retains normal growth and reproductive capacity. When these subpopulations coexist, the community achieves higher

antibiotic output without a net loss in overall fitness. This demonstrates a population-level strategy in which genetically distinct lineages carry out complementary roles for the benefit of the entire population.

Competitive interactions add an ecological layer to the developmental and genetic variation already present in *Streptomyces* colonies. Siderophore production is a good example; by scavenging iron for the producer, siderophores also impose iron limitation on nearby competitors. Zang et al. [77] recently showed that secretion of the siderophore coelichelin can increase *Bacillus subtilis* susceptibility to lytic phage infection, illustrating how a metabolite that mediates nutrient competition can also change competitor physiology in ways that alter community outcomes. These external cues generate heterogeneity even within a single colony. Cells at the boundary with a competitor often activate specific BGCs, secrete defensive or antagonistic metabolites, or change their developmental program, while cells deeper in the colony remain metabolically distinct. Traxler et al. [78] found that siderophore secretion by a neighbouring actinomycete triggered locally increased production of pigmented antibiotics and additional siderophores in *S. coelicolor*; this response was tightly localised to the interface between colonies and varied over time, with at least a dozen distinct acyl-dFO analogues produced sequentially as the colonies interacted. Repeated encounters with competitors can amplify these effects and select for stable specialisation. Over time, subpopulations that invest heavily in defence and metabolite secretion can emerge alongside subpopulations that prioritise growth and reproduction, reinforcing a division of labour that benefits the colony as a whole.

These layers of variation arise from dynamic genomes, complex regulation, and diverse ecological pressures. *Streptomyces* genomes undergo frequent horizontal gene transfer through integrative and conjugative elements (ICEs and AICEs) and contain BGCs positioned near chromosomal ends, where they evolve rapidly [79-81]. Regulatory networks further amplify differences in BGC expression even within clonal populations [82]. Ecologically, different species and strains inhabit soil, marine, and host-associated niches, and this diversity shapes their metabolite profiles [83-85]. Within a single colony, gradients in nutrients and signals lead to localised differences in morphology and metabolism [86-88]. For natural product discovery, these forms of heterogeneity mean that bulk assays often obscure rare high-producing cells that could otherwise yield valuable metabolites [89-91].

In short, the heterogeneity within *Streptomyces* colonies is not a random occurrence but a product of their adaptation to a resource-poor, competitive, and dynamically changing environment. The patchy availability of resources, division of labour among colony members, and the complex regulatory networks governing secondary metabolite production all contribute to this heterogeneity. These factors allow *Streptomyces* to adapt to its environment in a highly flexible and specialised manner, ensuring its survival and success in competitive soil ecosystems. As Hoskisson et al. [34] highlight, understanding the sources of this heterogeneity is crucial for future research, particularly in the fields of antibiotic discovery and the development of new biotechnological applications.

4. Unravelling the Morphological and Functional Heterogeneity in *Streptomyces* Fermentations

In recent years, significant progress has been made in understanding the inherent morphological heterogeneity of *Streptomyces* during industrial fermentations, a key factor influencing secondary metabolite production. The seminal work of van Veluw et al. [92] laid the foundation for understanding the dynamics of pellet formation in liquid cultures. Through a novel flow cytometry approach using the Complex Object Parametric Analyser and Sorter (COPAS), the authors identified two distinct subpopulations of pellets within *Streptomyces* fermentations, which include a uniform population of small mycelia and a more variable population of larger pellets. The functional significance of this morphological divergence was later uncovered through proteomic analysis, revealing that the larger pellets are enriched in stress-related and biosynthetic proteins, positioning them as specialised sites for secondary metabolite production. Conversely, the smaller pellets appear metabolically geared toward growth and replication. This work highlighted the critical role of pellet size in determining both the physiological state and the industrial potential of *Streptomyces* cultures [92].

Building on this foundational work, Zacchetti et al. [93] provided important mechanistic insights into the formation of heterogeneous pellets, demonstrating that aggregation between young germlings was mediated by specific glycans, acting as a key driver of pellet size heterogeneity. In contrast, fragmentation or the shearing off of viable mycelial parts acted as a counterbalancing force, dynamically shaping the final distribution of pellet sizes. Together, these findings establish a model where the interplay between aggregation and fragmentation creates a bimodal distribution of pellet sizes, as observed by van Veluw et al. [92]. These insights are pivotal for the rational design of *Streptomyces* morphology, opening avenues for engineering pellet formation to optimise metabolite yields.

The relationship between pellet morphology and metabolite production has been further elaborated by Wang et al. [94], who demonstrated that the optimal pellet size for secondary metabolite production is metabolite-specific. For example, smaller, denser pellets were found to enhance the production of undecylprodigiosin (Red) in *S. coelicolor*, while a different morphology was required for the production of actinorhodin (Act). Interestingly, Wang et al. [94] also showed that antibiotic treatments could directly manipulate mycelial architecture. Sub-inhibitory concentrations of thiostrepton promoted the formation of larger, more compact pellets, while spectinomycin induced the formation of smaller pellets. These findings suggest that antibiotics, traditionally considered inhibitors of growth, can also serve as chemical tools for morphologically reprogramming *Streptomyces*, providing a novel approach to optimising fermentation conditions and improving secondary metabolite production.

The role of antibiotics as signalling molecules is further exemplified by the study of jadomycin B (JdB), which acts as a ligand for the pseudo-receptor ScbR2 in *S. coelicolor* [95]. This interaction forms a feed-forward loop that regulates both morphological differentiation (via the *adpA* gene) and antibiotic production (via the *redD* gene). Notably, varying concentrations of JdB can skew the phenotypic response toward either differentiation or

enhanced antibiotic production, demonstrating that external chemical cues can finely tune the physiological state of *Streptomyces* populations. This discovery underscores the sophisticated regulatory networks that enable *Streptomyces* to adapt to environmental challenges, reinforcing the potential for engineered morphologies to optimise the production of specific metabolites.

Taken together, these studies illustrate the intricate relationship between *Streptomyces* morphology, metabolic specialisation, and secondary metabolite production. The functional division of labour observed in *Streptomyces* pellets opens new opportunities for optimising industrial fermentation processes. By leveraging these insights, researchers can not only better understand the biological underpinnings of *Streptomyces* heterogeneity but also develop more effective strategies for engineering microbial cultures with enhanced yields of valuable bioactive compounds.

5. Microfluidic Technology: A Toolkit for Deconstructing Heterogeneity

Microfluidics uses micrometre-scale channels and compartments to control fluids, cells, nutrients and gases with a precision that is impossible in conventional shake flasks or bioreactors. By reducing culture volumes to picoliters or nanoliters and running many experiments in parallel, droplet and chamber microfluidic platforms enable massively parallel experiments with very low reagent consumption and high temporal control. These platforms were first shown to enable ultrahigh-throughput screening and directed evolution by encapsulating single cells in droplets and screening millions of compartmentalised reactions [96].

Fluorescence-activated droplet sorting (FADS) is the microfluidic analogue of fluorescence-activated cell sorting (FACS). A particular advantage of FADS when compared to conventional sorting system, such as FACS, is that droplets provide a unique tool to link genotype and phenotype through compartmentalisation. Each droplet functions as an independent microreactor, allowing metabolites or reporter signals to accumulate to detectable levels even for slow-growing or low-titer producers [97]. This confinement makes it possible to measure rare phenotypes and to follow the complete life cycle of filamentous microbes inside a closed compartment [98, 99]. Moreover, encapsulated cells can be lysed for biochemical and genetic analyses. These advantages have been exploited for functional profiling of complex communities and for ultrahigh-throughput discovery of bioactive strains and activities. This distinction explains why FADS has become the preferred high-throughput method for screening filamentous producers [100, 101].

Recent studies have extended these approaches to filamentous actinomycetes, showing that droplets can support *Streptomyces* germination, vegetative growth and secondary metabolite production over several days, and can enrich hyperproducers by several hundred fold [102, 103]. The ability to cultivate productive mycelia in droplets and then interrogate and recover productive compartments also enables direct integration with downstream analytics. Lab-on-a-chip mass spectrometry (MS) workflow has been used to detect antibiotics and other secreted metabolites from individual droplets, providing direct chemical confirmation that the

productive phenotype observed by fluorescence corresponds to metabolite production [104]. These analytical integrations close the gap between phenotype and chemistry and set the stage for industry-relevant screening pipelines. Taken together, these features position microfluidics as a platform that both complements and overcomes the main limitations of FACS for *Streptomyces* screening.

5.1. The Challenge of FACS for *Streptomyces* analysis and sorting

FACS has long been established as an ideal ultra-high-throughput method for strain development in unicellular organisms like yeast and bacteria. Its power lies in the ability to screen and sort millions of individual cells from a liquid culture based on fluorescent markers at incredible speeds. For actinomycetes like *Streptomyces*, which are prolific producers of antibiotics and enzymes, applying FACS for reporter-guided metabolic engineering promises rapid strain improvement. However, a fundamental physical limitation has hindered its application: the filamentous, mycelial growth of *Streptomyces*. The typical mycelial fragments are far too large (260–950 μm) to pass through the standard $\sim 70 \mu\text{m}$ nozzle of a FACS instrument [105].

Early attempts to circumvent this issue involved creating and sorting protoplasts (cells with their cell walls removed). While technically possible, this approach has not been widely adopted due to the inherent fragility of protoplasts, very low post-sorting survival rates, and the fact that protoplasts do not represent the natural, productive mycelial form of the organism. For instance, Bai et al. [106] demonstrated the different buffers used in the optimisation for maintaining the osmotic pressure and viability of *Streptomyces* protoplasts up to $\sim 50\%$ viability for the development of a quantitative strategy at single-cell resolution for *Streptomyces*. This significant bottleneck limited the use of FACS for direct, high-throughput screening of industrially relevant *Streptomyces* cultures. A recent work has aimed to overcome this barrier by developing novel methodologies that bypass the need for protoplasts. Akhgari et al. [105] demonstrated that the pellet of a 3-days old culture of *Streptomyces* mycelia was subjected to ultrasonication, yielding mycelia fragments that were filtered through a cell-strainer cap prior to FACS.

Despite these efforts, a core limitation persists as FACS-based screening methods involve the screening of spores, protoplasts, or small mycelial fragments, which are not the same as the mature, differentiated mycelium responsible for sustained antibiotic production in industrial fermentations. This discrepancy has led to the development of microfluidic systems capable of encapsulating and analysing the entire filamentous life cycle of *Streptomyces*, offering a more accurate representation of the conditions under which secondary metabolites of interest are produced in industrial-scale fermentations.

5.2. Applications of Microfluidics in *Streptomyces* and Drug Discovery Research

5.2.1. Unravelling Lifecycle Heterogeneity and Single-Cell Behaviour

Microfluidics also enables the direct observation of *Streptomyces* development from a single spore, a crucial step in understanding lifecycle heterogeneity. Chen et al. [40] designed a chip with microwells and air chambers that mimic the natural water-air interface, crucial for aerial hyphae formation. This allowed them to observe the entire lifecycle of *Streptomyces coelicolor* and *S. griseus* from a single spore to mature mycelium, revealing differentiation processes at a micron scale. This single-cell perspective is vital for understanding heterogeneity in germination and development. Similarly, Koepff et al. [107] used microfluidic cultivation to investigate *Streptomyces lividans* under controlled conditions. Contrary to expectations of high intrinsic heterogeneity, they discovered remarkable uniformity in growth behaviour when environmental conditions were constant. Their key finding was that spores undergo long metabolic adaptation phases (up to > 30 hours) when introduced to new media, rather than employing a "persister" strategy. This suggests that the often-observed batch-to-batch variability in large-scale fermentations is likely a result of environmental gradients and poor controllability, not an intrinsic stochasticity at the single-cell level under stable conditions.

5.2.2. High-Throughput Screening in Industry-Relevant Conditions

Microfluidics has revolutionised high-throughput screening for *Streptomyces* by supporting the entire lifecycle of the organism, from germination to secondary metabolite production. Droplet-based microfluidics solves the limitation of traditional approaches, which are confined to screening spores or protoplasts, which do not represent the mycelial form responsible for antibiotic production in industrial fermentations. As demonstrated by Tu et al. [45], droplets act as picoliter-to-nanoliter bioreactors that can support the *Streptomyces*'s entire life cycle, including germination, vegetative growth, and critically, secondary metabolite production over 5-7 days. The study demonstrated a much better model for the *Streptomyces* fermentation process, allowing for the screening of hyperproducers in their productive mycelial form, achieving enrichment ratios of up to 334.2. For secreted products like antibiotics, Zhang et al. [108] developed the "REPID system" using core–shell microdroplets and a split GFP system to screen for filamentous fungi with high extracellular enzyme secretion. Although the system was demonstrated with fungi, the underlying approach is highly transferable to *Streptomyces*, which shares a similar filamentous growth form. Likewise, Samlali et al. [109] specifically addressed the challenge of sorting filamentous cells after long-term incubation by developing a low-voltage system to sort nanoliter droplets containing fungi based on their secretion of cell-wall-degrading enzymes after several days of growth. Crucially, these studies demonstrated that individual droplets can be interrogated for product formation and then sorted, either with dedicated droplet sorters or by adapting flow-cytometry/FACS workflows, so that droplets containing high-producing mycelia are physically recovered for downstream characterisation.

The integration of advanced detection systems in microfluidic platforms further enhances the specificity and capability of these screening systems. Wink et al. [104] and Mahler

et al. [110] used surfactant-stabilised droplets for long-term incubation and directly coupled them to mass spectrometry (MS). Their "chip-MS" setup allows for the *in situ* tracing of secondary metabolites like streptomycin from single droplets, confirming antibiotic production from fastidious cultures and complex environmental samples. Together, the combination of in-droplet cultivation, sensitive detection, and high-speed sorting creates a realistic, industry-relevant screening pipeline that identifies productive strains in their natural, mycelial state.

5.2.3. Studying Microbial Interactions Using Microfluidics

The study of microbial interactions is a crucial area of microbiological research, as understanding these complex dynamics can unveil new strategies for infection control, antibiotic discovery, and microbial ecology. However, traditional culture-based or bulk analytical methods often fail to capture the spatial and temporal heterogeneity that governs these interactions at the microscale. Building on this need for finer resolution, Terekhov et al. [111] demonstrated that biocompatible MDE droplets can be used for in-droplet co-cultivation of different living species, enabling detailed studies of how pathogens interact with one another, or with their hosts, in highly controlled microenvironments.

By combining droplet-generating machinery with FACS, next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS/MS) analysis of droplet-derived secretomes, the MDE–FACS platform offers unprecedented insight into the genotype–phenotype interactions of co-cultured microorganisms [111]. For instance, this system allows researchers to directly observe pathogen interactions within individual droplets, which contain both a "killer" strain (such as an antibiotic-producing *Streptomyces* isolate) and a "target" pathogen (such as *Staphylococcus aureus*). By incorporating fluorescent reporters for each species, droplets can be sorted based on fluorescence signatures that indicate bacterial inhibition, growth, or metabolic activity, enabling rapid identification of inhibitory interactions in real-time [111]. This high-throughput screening system far surpasses traditional agar-based methods in terms of both speed and scalability, offering a more efficient way to identify novel antibiotic-producing strains or understand the intricacies of pathogen dynamics.

Importantly, the MDE platform is compatible with downstream molecular and chemical analyses [111]. The genomes of isolated strains can be sequenced to identify specific biosynthetic gene clusters (BGCs) responsible for the observed inhibition [112], while LC-MS/MS analysis of the droplet secretomes offers direct chemical evidence of the metabolites involved. This integrated workflow, which links genetic profiles of the bacteria to their chemical outputs, has become a transformative tool in natural product research. It allows for the precise identification of the biosynthetic pathways responsible for antimicrobial activity, which is crucial for discovering novel antibiotics or understanding how microbial communities interact within a host or the environment. For example, MDE-enabled screening can be applied to identify probiotic candidates that inhibit gut pathogens, which cause dysbiosis [113, 114], helping to rationalise the development of next-generation probiotics tailored for gastrointestinal health [115–118], improved nutrient absorption, or reduced infection rates [119]. Similarly, in animal

agriculture and aquaculture, the platform can be used to pinpoint beneficial strains that competitively suppress zoonotic pathogens, offering alternatives to antibiotic use [120, 121].

The ability to study these interactions at the level of individual droplets not only accelerates the discovery of therapeutic or probiotic candidates, while deepens our understanding of the ecological and evolutionary pressures shaping pathogen behaviour. As this technology evolves, it holds promise for advancing the study of host-pathogen interactions and microbe-microbe dynamics in both clinical and agricultural contexts that were previously unattainable with traditional microbiological methods.

6. Raman Imaging: A Lens into the Chemical Heterogeneity of *Streptomyces*

Raman imaging has emerged as a transformative tool for dissecting the chemical and metabolic heterogeneity of *Streptomyces*, addressing long-standing limitations in traditional analytical methods. Conventional metabolomic techniques often rely on destructive sampling and yield only pool-averaged measurements, obscuring the spatial and temporal dynamics that govern metabolite production within a biological sample [122, 123]. In contrast, Raman imaging, particularly single-cell Raman microspectroscopy, provides a label-free, non-destructive, and chemically specific means of probing living cells [124]. By detecting the inelastic scattering of light from molecular bonds, it generates a spectroscopic “fingerprint” that reflects the unique chemical state of each cell. This shift from bulk analyses to spatially resolved, single-cell measurements has fundamentally changed how researchers interrogate heterogeneity, enabling direct visualisation of where and when biosynthetic activity occurs within the mycelial network [124].

The power and feasibility of Raman-based analysis in *Streptomyces* were first demonstrated in one of the earliest UV resonance Raman studies, where bulk spectra classified species with >94% accuracy and single-cell spectra achieved 80–93% accuracy despite the microorganism’s filamentous hyphal structure [125]. Critically, the study showed that even a single Raman spectrum can capture the complete chemical and physiological state of a *Streptomyces* hyphal cell, confirming that single-cell phenotyping is viable in these multicellular bacteria. It also revealed condition-dependent chemical heterogeneity, whereby young cultures and lipid-rich cells exhibited uniform spectra, while early lipid-producing cells displayed mixed spectral signatures, reflecting intracellular chemical variation. These foundational insights established Raman spectroscopy as a sensitive platform capable of resolving both species-level diversity and fine-scale metabolic heterogeneity.

6.1. Spatial and Temporal Mapping of Metabolite Production

Raman imaging has provided compelling evidence that secondary metabolite production in *Streptomyces* is not uniform but closely tied to morphological development, with metabolites localised in specific regions of the mycelium. One key demonstration of this is the work of Miyaoka et al. [42], who used resonance Raman spectroscopy to study *Streptomyces nodosus* producing the polyene antibiotic amphotericin B (AmB). By leveraging the resonance

Raman effect, which enhances the signal when the laser wavelength matches the molecule's electronic absorption, the researchers were able to detect AmB within the hyphae and map its heterogeneous distribution. This approach also allowed them to monitor the time-dependent accumulation of AmB alongside mycelial growth, providing insights into its production dynamics within the colony. Furthermore, the technique was sensitive enough to detect Raman spectral shifts, enabling the identification of the molecular association state of AmB *in situ* within the cellular environment. Similarly, in a more recent study, Suwa et al. ^[126] proposed a newer method that directly analyses the secondary metabolite production within *Streptomyces* colonies on agar dishes using multivariate Raman spectral analysis with machine learning algorithms.

Raman imaging has also revealed the dynamic nature of metabolite localisation in *Streptomyces avermitilis*, where the distribution of the antihelmintic agent avermectin varies based on both developmental stage and culture conditions ^[127]. In solid cultures, avermectin was primarily localised in the later-stage, spore-bearing mycelium and spiral spore chains, but not in the early vegetative mycelium. In contrast, when cultured in liquid, avermectin accumulated within mycelial pellets formed at an earlier morphological stage (MII). This research indicated that morphological differentiation alone is not an accurate predictor of metabolic activity, as the chemical profiles of mycelia at the same stage (MII) varied considerably between solid and liquid cultures ^[127].

The integration of Raman imaging into *Streptomyces* research marks a paradigm shift from a bulk, averaged perspective to a single-cell resolution, spatially resolved understanding of metabolic heterogeneity. The ability to track metabolite production *in situ*, label-free, and dynamically from a growing colony is unparalleled ^[126]. By linking specific chemical profiles to morphological features, Raman imaging provides insights into the complex regulatory network that governs the activation of biosynthetic gene clusters. The findings from these studies suggest that heterogeneity is not merely random variation but a structured, ecologically relevant phenomenon. The observed spatial segregation of metabolites like amphotericin B and avermectin points to functional compartmentalisation within the *Streptomyces* colony ^[127], which could be crucial for optimising production or mitigating self-toxicity.

For industrial applications, the ability to rapidly screen high-producing strains or non-destructively monitor fermentation processes in real time could lead to substantial gains in yield and efficiency ^[128]. Evidence from studies in other microorganisms has already shown that integrating microfluidic platforms with Raman-based single-cell analysis enables high-throughput trapping, cultivation, and phenotyping at unprecedented resolution ^[129, 130]. Although there are only limited studies that combine a microfluidic system with Raman spectroscopy, these successes highlight a clear opportunity for *Streptomyces* research. Future work should focus on adapting and optimising such integrated microfluidic-Raman workflows for filamentous bacteria, where controlled microscale environments could stabilise growth, isolate distinct morphological states, and enable systematic interrogation of metabolic heterogeneity. Developing these combinatorial platforms would not only advance natural

product discovery but also create a powerful screening pipeline for strain improvement and industrial process optimisation.

7. Conclusions

Understanding and harnessing *Streptomyces* heterogeneity has become central to improving the discovery and production of bioactive compounds. Microfluidic technologies have shifted the field from a bulk, population-averaged perspective to a high-resolution, single-cell analysis that can track cellular behaviours and secondary metabolite production with unprecedented detail. These advancements are enabling more accurate strain selection, revealing the regulatory networks that govern biosynthetic gene cluster activation, and providing powerful new tools for metabolic engineering. The future of *Streptomyces* research lies in combining these advanced microfluidic techniques with high-resolution genomics, metabolomics, and AI-driven optimisation. By integrating Raman imaging with genome mining, mutagenesis, and other analytics, we can accelerate natural product discovery, refine strain optimisation processes, and push the boundaries of industrial biotechnological applications. As these technologies converge, they will not only deepen our understanding of *Streptomyces* biology but also transform how we approach natural product production, bringing us closer to harnessing the full potential of these remarkable microorganisms.

Funding: This research and the APC were funded by the UNNC CBI Seed Grant (grant code: I01240300006) awarded to LT-HT. The author also thanks the Zhejiang Provincial Youth Thousand Talents Program for financial support.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Tan LT-H, Chan K-G, Khan TM, *et al.* *Streptomyces* sp. MUM212 as a Source of Antioxidants with Radical Scavenging and Metal Chelating Properties. *Front Pharmacol* 2017; Volume 8 - 2017.
2. Tan LT-H, Mahendra CK, Yow Y-Y, *et al.* *Streptomyces* sp. MUM273b: A mangrove-derived potential source for antioxidant and UVB radiation protectants. *MicrobiologyOpen* 2019; 8(10): e859.
3. Woodruff HB. Selman A. Waksman, winner of the 1952 Nobel Prize for physiology or medicine. *Appl Environ Microbiol* 2014; 80(1): 2-8.
4. Schlimpert S and Elliot MA. The best of both worlds—*Streptomyces coelicolor* and *Streptomyces venezuelae* as model species for studying antibiotic production and bacterial multicellular development. *J Bacteriol* 2023; 205(7): e00153-23.
5. Thye AY-K, Letchumanan V, Tan LT-H, *et al.* Malaysia's Breakthrough in Modern Actinobacteria (MOD-ACTINO) Drug Discovery Research. *Prog Microbes Mol Biol* 2022; 5(1): a0000275.
6. Ang W-S, Law JW-F, Kumari Y, *et al.* Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in *Streptomyces*. *Prog Microbes Mol Biol* 2024; 7(1): a0000453.
7. Elsalam RM, Goh KW, Mahadi M, *et al.* The Antibacterial Activities of Secondary Metabolites Derived from *Streptomyces* sp. *Prog Microbes Mol Biol* 2022; 5(1): a0000281.
8. Donald L, Pipite A, Subramani R, *et al.* *Streptomyces*: Still the Biggest Producer of New Natural Secondary Metabolites, a Current Perspective. *Microbiol Res (Pavia)* 2022; 13(3): 418-465.

9. Beroogui O and Errachidi F. Streptomyces at the Heart of Several Sectors to Support Practical and Sustainable Applications: A Review. *Prog Microbes Mol Biol* 2023; 6(1): a0000345.
10. Tan LT-H, Ser H-L, Yin W-F, *et al.* Investigation of Antioxidative and Anticancer Potentials of Streptomyces sp. MUM256 Isolated from Malaysia Mangrove Soil. *Front Microbiol* 2015; Volume 6 - 2015.
11. Tan LT-H, Chan K-G, Pusparajah P, *et al.* Mangrove derived Streptomyces sp. MUM265 as a potential source of antioxidant and anticolon-cancer agents. *BMC Microbiol* 2019; 19(1): 38.
12. Tan LT-H, Chan C-K, Chan K-G, *et al.* Streptomyces sp. MUM256: A Source for Apoptosis Inducing and Cell Cycle-Arresting Bioactive Compounds against Colon Cancer Cells. *Cancers (Basel)* 2019; 11(11): 1742.
13. Kemung HM, Tan LT-H, Khan TM, *et al.* Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs. *Front Microbiol* 2018; Volume 9 - 2018.
14. Pusparajah P, Letchumanan V, Law JW-F, *et al.* Streptomyces sp.—A Treasure Trove of Weapons to Combat Methicillin-Resistant *Staphylococcus aureus* Biofilm Associated with Biomedical Devices. *Int J Mol Sci* 2021; 22(17): 9360.
15. Loo K-Y, Tan LT-H, Law JW-F, *et al.* Detection of multidrug resistant *Vibrio parahaemolyticus* and anti-*Vibrio* Streptomyces sp. MUM 178J. *Prog Microbes Mol Biol* 2023; 6(1): a0000347.
16. Loo K-Y, Tan LT-H, Law JW-F, *et al.* Complete Whole Genome Sequence of *Vibrio parahaemolyticus* RP0132 Strain Isolated from Shrimp in Malaysia. *Prog Microbes Mol Biol* 2023; 6(1): a0000388.
17. Goh SY, Chua K-O, Khan SA, *et al.* Genomic and Resistome Analyses of *Elizabethkingia anophelis* Strain B2D isolated from Dental Plaque of Patient. *Prog Microbes Mol Biol* 2024; 7(1): a0000440.
18. Rizki LP, Murni IK, Aman AT, *et al.* Environmental Metagenomic Analysis of "ESKAPE" Pathogens in the Pediatric Intensive Care Unit of General Hospital Yogyakarta Indonesia. *Prog Microbes Mol Biol* 2024; 7(1): a0000398.
19. Loo K-Y, Law JW-F, Tan LT-H, *et al.* The Burden of *Vibrio* sp. Infections – A Scoping Review. *Prog Microbes Mol Biol* 2023; 6(1): a0000340.
20. Kuai YH, Law JW-F, Ong YS, *et al.* Role of SarA in *Staphylococcus aureus*: A Virulence Target For Therapeutic Strategies. *Prog Microbes Mol Biol* 2024; 7(1): a0000444.
21. Talbi C, Elmarrkechy S, Youssfi M, *et al.* Bacterial Exopolysaccharides: From Production to Functional Features. *Prog Microbes Mol Biol* 2023; 6(1): a0000384.
22. Chong KJ, Feng H, Letchumanan V, *et al.* Tackling Microbial Resistance and Emerging Pathogens with Next-Generation Antibiotics. *Prog Microbes Mol Biol* 2024; 7(1): a0000447.
23. Loo K-Y, Tan LT-H, Law JW-F, *et al.* *Vibrio parahaemolyticus*: Exploring its Incidence in Malaysia and the Potential of Streptomyces sp. as an Anti-*Vibrio* Agent. *Prog Microbes Mol Biol* 2023; 6(1): a0000334.
24. Kim DG, Gu B, Cha Y, *et al.* Engineered CRISPR-Cas9 for Streptomyces sp. genome editing to improve specialized metabolite production. *Nat Comm* 2025; 16(1): 874.
25. Lee Y, Hwang S, Kim W, *et al.* CRISPR-aided genome engineering for secondary metabolite biosynthesis in Streptomyces. *J Ind Microbiol Biotechnol* 2024; 51.
26. Yang B, Li Z, Zhang J, *et al.* Scalable secondary metabolite production in Streptomyces using a plug-and-play system. *Nat Biotechnol* 2025.

27. Breitling R, Avbelj M, Bilyk O, *et al.* Synthetic biology approaches to actinomycete strain improvement. *FEMS Microbiol Lett* 2021; 368(10).

28. Xu J, Zhang J, Zhuo J, *et al.* Activation and mechanism of a cryptic oviedomycin gene cluster via the disruption of a global regulatory gene, *adpA*, in *Streptomyces ansochromogenes*. *J Biol Chem* 2017; 292(48): 19708-19720.

29. Krysenko S. Current Approaches for Genetic Manipulation of *Streptomyces* spp.—Key Bacteria for Biotechnology and Environment. *BioTech* 2025; 14(1): 3.

30. Liu G, Chater KF, Chandra G, *et al.* Molecular regulation of antibiotic biosynthesis in streptomycetes. *Microbiol Mol Biol Rev* 2013; 77(1): 112-43.

31. Hoskisson Paul A and Seipke Ryan F. Cryptic or Silent? The Known Unknowns, Unknown Knowns, and Unknown Unknowns of Secondary Metabolism. *mBio* 2020; 11(5): 10.1128/mbio.02642-20.

32. Becerril A, Pérez-Victoria I, Ye S, *et al.* Discovery of Cryptic Largimycins in *Streptomyces* Reveals Novel Biosynthetic Avenues Enriching the Structural Diversity of the Leinamycin Family. *ACS Chem Biol* 2020; 15(6): 1541-1553.

33. Jones SE and Elliot MA. ‘Exploring’ the regulation of *Streptomyces* growth and development. *Curr Opin Microbiol* 2018; 42: 25-30.

34. Hoskisson PA, Barona-Gómez F, and Rozen DE. Phenotypic heterogeneity in *Streptomyces* colonies. *Curr Opin Microbiol* 2024; 78: 102448.

35. Flärdh K and Buttner MJ. *Streptomyces* morphogenetics: dissecting differentiation in a filamentous bacterium. *Nat Rev Microbiol* 2009; 7(1): 36-49.

36. Xu Y and Vetsigian K. Phenotypic variability and community interactions of germinating *Streptomyces* spores. *Sci Rep* 2017; 7(1): 699.

37. Tan LT-H, Lee L-H, and Goh B-H. Critical review of fermentation and extraction of anti-Vibrio compounds from *Streptomyces*. *Prog Microbes Mol Biol* 2020; 3(1): a0000051.

38. Traxler MF and Rozen DE. Ecological drivers of division of labour in *Streptomyces*. *Curr Opin Microbiol* 2022; 67: 102148.

39. Zambri MP, Williams MA, and Elliot MA. *Chapter Five - How Streptomyces thrive: Advancing our understanding of classical development and uncovering new behaviors*, in *Adv Microb Physiol*, R.K. Poole and D.J. Kelly, Editors. 2022, Academic Press. p. 203-236.

40. Chen D, Nie M, Tang W, *et al.* Whole lifecycle observation of single-spore germinated *Streptomyces* using a nanogap-stabilized microfluidic chip. *mLife* 2022; 1(3): 341-349.

41. Rodrigues JP, Prova SS, Moraes LAB, *et al.* Characterization and mapping of secondary metabolites of *Streptomyces* sp. from caatinga by desorption electrospray ionization mass spectrometry (DESI-MS). *Anal Bioanal Chem* 2018; 410(27): 7135-7144.

42. Miyaoka R, Hosokawa M, Ando M, *et al.* In Situ Detection of Antibiotic Amphotericin B Produced in *Streptomyces nodosus* Using Raman Microspectroscopy. *Mar Drugs* 2014; 12(5): 2827-2839.

43. Cao X, Luo Z, Zeng W, *et al.* Enhanced avermectin production by *Streptomyces avermitilis* ATCC 31267 using high-throughput screening aided by fluorescence-activated cell sorting. *Appl Microbiol Biotechnol* 2018; 102(2): 703-712.

44. Hua E, Zhang Y, Yun K, *et al.* Whole-Cell Biosensor and Producer Co-cultivation-Based Microfluidic Platform for Screening *Saccharopolyspora erythraea* with Hyper Erythromycin Production. *ACS Synth Biol* 2022; 11(8): 2697-2708.

45. Tu R, Zhang Y, Hua E, *et al.* Droplet-based microfluidic platform for high-throughput screening of *Streptomyces*. *Commun Biol* 2021; 4(1): 647.

46. Lee N, Hwang S, Kim W, *et al.* Systems and synthetic biology to elucidate secondary metabolite biosynthetic gene clusters encoded in *Streptomyces* genomes. *Nat Prod Rep* 2021; 38(7): 1330-1361.

47. Arias P, Fernández-Moreno MA, and Malpartida F. Characterization of the pathway-specific positive transcriptional regulator for actinorhodin biosynthesis in *Streptomyces coelicolor* A3(2) as a DNA-binding protein. *J Bacteriol* 1999; 181(22): 6958-68.

48. Takano E, Gramajo HC, Strauch E, *et al.* Transcriptional regulation of the *redD* transcriptional activator gene accounts for growth-phase-dependent production of the antibiotic undecylprodigiosin in *Streptomyces coelicolor* A3(2). *Mol Microbiol* 1992; 6(19): 2797-804.

49. Fujii T, Gramajo HC, Takano E, *et al.* *redD* and *actII-ORF4*, pathway-specific regulatory genes for antibiotic production in *Streptomyces coelicolor* A3(2), are transcribed in vitro by an RNA polymerase holoenzyme containing sigma *hrdD*. *J Bacteriol* 1996; 178(11): 3402-5.

50. Augustijn HE, van Nassauw D, Cernat S, *et al.* Regulatory Genes as Beacons for Discovery and Prioritization of Biosynthetic Gene Clusters in *Streptomyces*. *Biochemistry* 2025; 64(13): 2877-2885.

51. Mohite OS, Jørgensen TS, Booth TJ, *et al.* Pangenome mining of the *Streptomyces* genus redefines species' biosynthetic potential. *Genome Biol* 2025; 26(1): 9.

52. Law JW-F, Letchumanan V, Hong K-W, *et al.* *Streptomyces learnhanii* sp. nov., unveiling a Mangrove-Derived Novel "Modern Actinobacteria" in Malaysia. *Prog Microbes Mol Biol* 2023; 6(1): a0000342.

53. Law JWF, Tan LT-H, Letchumanan V, *et al.* *Streptomyces griseiviridis* sp. nov., a Novel "Modern Actinobacteria" isolated from Malaysia Mangrove Soil. *Prog Microbes Mol Biol* 2023; 6(1): a0000270.

54. Pusparajah P, Law JW-F, Chan K-G, *et al.* Whole-Genome Sequence of *Streptomyces pluripotens* strain MUM 16J, a Potential Resource of Glycopeptide Antibiotic and Biocontrol Agent against Biofilm-forming Bacteria. *Prog Microbes Mol Biol* 2023; 6(1): a0000330.

55. Zhao M, Yang Z, Li X, *et al.* Development of Integrated Vectors with Strong Constitutive Promoters for High-Yield Antibiotic Production in Mangrove-Derived *Streptomyces*. *Mar Drugs* 2024; 22(2).

56. Wang W, Li X, Wang J, *et al.* An Engineered Strong Promoter for Streptomycetes. *Appl Environ Microbiol* 2013; 79(14): 4484-4492.

57. Siegl T, Tokovenko B, Myronovskiy M, *et al.* Design, construction and characterisation of a synthetic promoter library for fine-tuned gene expression in actinomycetes. *Metab Eng* 2013; 19: 98-106.

58. Seghezzi N, Amar P, Koebmann B, *et al.* The construction of a library of synthetic promoters revealed some specific features of strong *Streptomyces* promoters. *Appl Microbiol Biotechnol* 2011; 90(2): 615-23.

59. Ji C-H, Kim J-P, and Kang H-S. Library of Synthetic *Streptomyces* Regulatory Sequences for Use in Promoter Engineering of Natural Product Biosynthetic Gene Clusters. *ACS Synth Biol* 2018; 7(8): 1946-1955.

60. Alberti F and Corre C. Editing streptomycete genomes in the CRISPR/Cas9 age. *Nat Prod Rep* 2019; 36(9): 1237-1248.

61. Cobb RE, Wang Y, and Zhao H. High-efficiency multiplex genome editing of *Streptomyces* species using an engineered CRISPR/Cas system. *ACS Synth Biol* 2015; 4(6): 723-8.

62. Zhu S, Duan Y, and Huang Y. The Application of Ribosome Engineering to Natural Product Discovery and Yield Improvement in *Streptomyces*. *Antibiotics (Basel)* 2019; 8(3).

63. Yan H, Li S, and Wang W. Reprogramming naturally evolved switches for *Streptomyces* chassis development. *Trends Biotechnol* 2025; 43(1): 12-15.

64. Zou Y, Wang R, Liu Z, *et al.* Development of a versatile chassis for the efficient production of diverse type II polyketides. *Nat Comm* 2025; 16(1): 7321.

65. Ahmed Y, Rebets Y, Estévez MR, *et al.* Engineering of *Streptomyces lividans* for heterologous expression of secondary metabolite gene clusters. *Microb Cell Factories* 2020; 19(1): 5.

66. Kallifidas D, Jiang G, Ding Y, *et al.* Rational engineering of *Streptomyces albus* J1074 for the overexpression of secondary metabolite gene clusters. *Microb Cell Factories* 2018; 17(1): 25.

67. Zheng J, Li Y, Guan H, *et al.* Enhancement of neomycin production by engineering the entire biosynthetic gene cluster and feeding key precursors in *Streptomyces fradiae* CGMCC 4.576. *Appl Microbiol Biotechnol* 2019; 103(5): 2263-2275.

68. Liu R, Deng Z, and Liu T. *Streptomyces* species: Ideal chassis for natural product discovery and overproduction. *Metab Eng* 2018; 50: 74-84.

69. Schniete JK, Cruz-Morales P, Selem-Mojica N, *et al.* Expanding Primary Metabolism Helps Generate the Metabolic Robustness To Facilitate Antibiotic Biosynthesis in *Streptomyces*. *mBio* 2018; 9(1).

70. Kittikunapong C, Ye S, Magadán-Corpas P, *et al.* Reconstruction of a Genome-Scale Metabolic Model of *Streptomyces albus* J1074: Improved Engineering Strategies in Natural Product Synthesis. *Metabolites* 2021; 11(5).

71. Del Carratore F, Hanko EKR, Schmidt K, *et al.* Engineering *Streptomyces coelicolor* for heterologous expression of the thiopeptide GE2270A—A cautionary tale. *J Ind Microbiol Biotechnol* 2025; 52.

72. Zhao Y, Li G, Chen Y, *et al.* Challenges and Advances in Genome Editing Technologies in *Streptomyces*. *Biomolecules* 2020; 10(5): 734.

73. Thomas T. Off-target Cas9 crystallized. *Nat Struct Mol Biol* 2022; 29(12): 1147-1147.

74. Salem SM, Weidenbach S, and Rohr J. Two Cooperative Glycosyltransferases Are Responsible for the Sugar Diversity of Saquayamycins Isolated from *Streptomyces* sp. KY 40-1. *ACS Chem Biol* 2017; 12(10): 2529-2534.

75. Norte DM, Avitia-Dominguez LA, and Rozen DE. Evolution and Ecology of *Streptomyces*. *Annu Rev Microbiol* 2025; 79(Volume 79, 2025): 383-403.

76. Zhang Z, Du C, de Bary F, *et al.* Antibiotic production in *Streptomyces* is organized by a division of labor through terminal genomic differentiation. *Sci Adv* 2020; 6(3): eaay5781.

77. Zang Z, Zhang C, Park KJ, *et al.* *Streptomyces* secretes a siderophore that sensitizes competitor bacteria to phage infection. *Nat Microbiol* 2025; 10(2): 362-373.

78. Traxler MF, Seyedsayamdst MR, Clardy J, *et al.* Interspecies modulation of bacterial development through iron competition and siderophore piracy. *Mol Microbiol* 2012; 86(3): 628-44.

79. Choufa C, Tidjani A-R, Gauthier A, *et al.* Prevalence and mobility of integrative and conjugative elements within a *Streptomyces* natural population. *Front Microbiol* 2022; Volume 13 - 2022.

80. te Poole EM, Bolhuis H, and Dijkhuizen L. Actinomycete integrative and conjugative elements. *Antonie Van Leeuwenhoek* 2008; 94(1): 127-43.

81. Bury-Moné S, Thibessard A, Lioy VS, *et al.* Dynamics of the *Streptomyces* chromosome: chance and necessity. *Trends Genet* 2023; 39(11): 873-887.

82. Qi Y, Nepal KK, and Blodgett JAV. A comparative metabologenomic approach reveals mechanistic insights into *Streptomyces* antibiotic crypticity. *Proc Natl Acad Sci* 2021; 118(31): e2103515118.

83. Gallagher KA, Rauscher K, Pavan Ioca L, *et al.* Phylogenetic and chemical diversity of a hybrid-isoprenoid-producing streptomycete lineage. *Appl Environ Microbiol* 2013; 79(22): 6894-902.

84. Jackson SA, Crossman L, Almeida EL, *et al.* Diverse and Abundant Secondary Metabolism Biosynthetic Gene Clusters in the Genomes of Marine Sponge Derived *Streptomyces* spp. Isolates. *Mar Drugs* 2018; 16(2).

85. Hiltner JK, Hunter IS, and Hoskisson PA. *Chapter Four - Tailoring Specialized Metabolite Production in Streptomyces*, in *Adv Appl Microbiol*, S. Sariaslani and G.M. Gadd, Editors. 2015, Academic Press. p. 237-255.

86. Vetsigian K, Jajoo R, and Kishony R. Structure and evolution of *Streptomyces* interaction networks in soil and in silico. *PLoS Biol* 2011; 9(10): e1001184.

87. Challis GL and Hopwood DA. Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by *Streptomyces* species. *Proc Natl Acad Sci U S A* 2003; 100 Suppl 2(Suppl 2): 14555-61.

88. Avitia Domínguez LA, Yu Z, Chopra V, *et al.* Factors that influence the caste ratio in a bacterial division of labour. *Philos Trans R Soc Lond B Biol Sci* 2025; 380(1922): 20230267.

89. Samernate T, Htoo HH, Sugie J, *et al.* High-Resolution Bacterial Cytological Profiling Reveals Intrapopulation Morphological Variations upon Antibiotic Exposure. *Antimicrob Agents Chemother* 2023; 67(2): e01307-22.

90. Koepff J, Sachs CC, Wiechert W, *et al.* Germination and Growth Analysis of *Streptomyces lividans* at the Single-Cell Level Under Varying Medium Compositions. *Front Microbiol* 2018; 9: 2680.

91. Gough A, Shun TY, Lansing Taylor D, *et al.* A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. *Methods* 2016; 96: 12-26.

92. van Veluw GJ, Petrus MLC, Gubbens J, *et al.* Analysis of two distinct mycelial populations in liquid-grown *Streptomyces* cultures using a flow cytometry-based proteomics approach. *Appl Microbiol Biotechnol* 2012; 96(5): 1301-1312.

93. Zucchetti B, Willemse J, Recter B, *et al.* Aggregation of germlings is a major contributing factor towards mycelial heterogeneity of *Streptomyces*. *Sci Rep* 2016; 6(1): 27045.

94. Wang H, Zhao G, and Ding X. Morphology engineering of *Streptomyces coelicolor* M145 by sub-inhibitory concentrations of antibiotics. *Sci Rep* 2017; 7(1): 13226.

95. Wang W, Ji J, Li X, *et al.* Angucyclines as signals modulate the behaviors of *Streptomyces coelicolor*. *Proc Natl Acad Sci U S A* 2014; 111(15): 5688-93.

96. Agresti JJ, Antipov E, Abate AR, *et al.* Ultrahigh-throughput screening in drop-based microfluidics for directed evolution. *Proc Natl Acad Sci U S A* 2010; 107(9): 4004-9.

97. Bowman EK and Alper HS. Microdroplet-Assisted Screening of Biomolecule Production for Metabolic Engineering Applications. *Trends Biotechnol* 2020; 38(7): 701-714.

98. Zucchetti B, Wösten HAB, and Claessen D. Multiscale heterogeneity in filamentous microbes. *Biotechnol Adv* 2018; 36(8): 2138-2149.

99. Ugolini GS, Wang M, Secchi E, *et al.* Microfluidic approaches in microbial ecology. *Lab Chip* 2024; 24(5): 1394-1418.

100. Baret JC, Miller OJ, Taly V, *et al.* Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. *Lab Chip* 2009; 9(13): 1850-8.
101. Zang E, Brandes S, Tovar M, *et al.* Real-time image processing for label-free enrichment of Actinobacteria cultivated in picolitre droplets. *Lab Chip* 2013; 13(18): 3707-3713.
102. Terekhov SS, Smirnov IV, Malakhova MV, *et al.* Ultrahigh-throughput functional profiling of microbiota communities. *Proc Natl Acad Sci U S A* 2018; 115(38): 9551-9556.
103. Zhang Y, Zhang X, and Wang M. Product-driven high-throughput screening of industrial filamentous actinomycetes. *Trends Biotechnol* 2023; 41(9): 1109-1112.
104. Wink K, Mahler L, Beulig JR, *et al.* An integrated chip-mass spectrometry and epifluorescence approach for online monitoring of bioactive metabolites from incubated Actinobacteria in picoliter droplets. *Anal Bioanal Chem* 2018; 410(29): 7679-7687.
105. Akhgari A, Baral B, Koroleva A, *et al.* Single cell mutant selection for metabolic engineering of actinomycetes. *Metab Eng* 2022; 73: 124-133.
106. Bai C, Zhang Y, Zhao X, *et al.* Exploiting a precise design of universal synthetic modular regulatory elements to unlock the microbial natural products in Streptomyces. *Proc Natl Acad Sci* 2015; 112(39): 12181-12186.
107. Koepff J, Sachs CC, Wiechert W, *et al.* Germination and Growth Analysis of Streptomyces lividans at the Single-Cell Level Under Varying Medium Compositions. *Frontiers in Microbiology* 2018; Volume 9 - 2018.
108. Zhang C, Wu X, Song F, *et al.* Core–Shell Droplet-Based Microfluidic Screening System for Filamentous Fungi. *ACS Sensors* 2023; 8(9): 3468-3477.
109. Samlali K, Alves CL, Jezernik M, *et al.* Droplet digital microfluidic system for screening filamentous fungi based on enzymatic activity. *Microsyst Nanoeng* 2022; 8(1): 123.
110. Mahler L, Wink K, Beulig RJ, *et al.* Detection of antibiotics synthetized in microfluidic picolitre-droplets by various actinobacteria. *Sci Rep* 2018; 8(1): 13087.
111. Terekhov SS, Smirnov IV, Stepanova AV, *et al.* Microfluidic droplet platform for ultrahigh-throughput single-cell screening of biodiversity. *Proc Natl Acad Sci* 2017; 114(10): 2550-2555.
112. Loo K-Y, Tan LT-H, Chua K-O, *et al.* Complete Whole-Genome Sequence of Streptomyces sp. MUM 178J, a Potential Anti-Vibrio Agent. *Prog Microbes Mol Biol* 2024; 7(1): a0000399.
113. Kandasamy S, Letchumanan V, Hong KW, *et al.* The Role of Human Gut Microbe Ruminococcus gnavus in Inflammatory Diseases. *Prog Microbes Mol Biol* 2023; 6(1): a0000396.
114. Thye AY-K, Tan LT-H, Law JW-F, *et al.* Long COVID-19: Psychological symptoms in COVID-19 and probiotics as an adjunct therapy. *Prog Microbes Mol Biol* 2022; 5(1): a0000267.
115. Loo K-Y, Thong JYH, Tan LT-H, *et al.* A Current Overview of Next-Generation Probiotics and Their Prospects in Health and Disease Management. *Prog Microbes Mol Biol* 2024; 7(1): a0000457.
116. Kong GY-E, Letchumanan V, Tan LT-H, *et al.* Gut Microbiome in Obsessive Compulsive Disorder: Potential of Probiotics as an Adjuvant Therapy. *Prog Microbes Mol Biol* 2022; 5(1): a0000272.
117. Lee L-H. Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions. *Prog Microbes Mol Biol* 2025; 8(1): a0000459.
118. Yi Tay T, Zhi Wong MY, Wee AS, *et al.* Clinical Applications of Probiotics in Atopic Dermatitis. *Prog Microbes Mol Biol* 2025; 8(1): a0000473.

119. Goh JXH, Tan LT-H, Law JW-F, *et al.* Probiotics: Comprehensive Exploration of the Growth Promotion Mechanisms in Shrimps. *Prog Microbes Mol Biol* 2023; 6(1): a0000324.
120. Goh JXH, Tan LT-H, Law JW-F, *et al.* Streptomyces sp. MUM 195J: A Promising Probiotic for Controlling *Vibrio parahaemolyticus* Infection in Aquaculture. *Prog Microbes Mol Biol* 2024; 7(1): a0000443.
121. Tan LT-H, Chan K-G, Lee L-H, *et al.* Streptomyces Bacteria as Potential Probiotics in Aquaculture. *Front Microbiol* 2016; Volume 7 - 2016.
122. Sekurova ON, Zehl M, Predl M, *et al.* Targeted Metabolomics and High-Throughput RNA Sequencing-Based Transcriptomics Reveal Massive Changes in the *Streptomyces venezuelae* NRRL B-65442 Metabolism Caused by Ethanol Shock. *Microbiol Spectr* 2022; 10(6): e0367222.
123. Zulkefly A, Wan Azman WN, Omar J, *et al.* Identification of Potential Biomarkers and Metabolic Changes in the Serum of Breast Lump Patients Among Kelantanese Based on 1H NMR Metabolomics. *Prog Microbes Mol Biol* 2023; 6(1): a0000392.
124. Shigeto S and Takeshita N. Raman Micro-spectroscopy and Imaging of Filamentous Fungi. *Microbes Environ* 2022; 37(6).
125. Walter A, Schumacher W, Bocklitz T, *et al.* From Bulk to Single-Cell Classification of the Filamentous Growing *Streptomyces* Bacteria by Means of Raman Spectroscopy. *Appl Spectrosc* 2011; 65(10): 1116-1125.
126. Suwa S, Ando M, Nakashima T, *et al.* In Situ Raman Hyperspectral Analysis of Microbial Colonies for Secondary Metabolites Screening. *Anal Chem* 2024; 96(37): 14909-14917.
127. Horii S, Samuel AZ, Nakashima T, *et al.* Mycelial differentiation linked avermectin production in *Streptomyces avermitilis* studied with Raman imaging. *Appl Microbiol Biotechnol* 2023; 107(1): 369-378.
128. Hagedorn J, Ramos G, Ressurreição M, *et al.* Raman-Enabled Predictions of Protein Content and Metabolites in Biopharmaceutical *Saccharomyces cerevisiae* Fermentations. *Eng Life Sci* 2024; 24(12): e202400045.
129. Wang X, Ren L, Su Y, *et al.* Raman-Activated Droplet Sorting (RADS) for Label-Free High-Throughput Screening of Microalgal Single-Cells. *Anal Chem* 2017; 89(22): 12569-12577.
130. Hu L, Luo R, Wang D, *et al.* SERS-based microdroplet platform for high-throughput screening of *Escherichia coli* strains for the efficient biosynthesis of D-phenyllactic acid. *Front Bioeng Biotechnol* 2024; 12: 1470830.



Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:

Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.